晚期前列腺癌患者的管理。第一部分:中高危和局部晚期疾病、生化复发及激素治疗副作用:2022年晚期前列腺癌共识会议报告
2022年晚期前列腺癌共识会议(APCCC 2022)通过改良Delphi流程,由117位国际专家制定198个多选题,经105位专家组成员网络投票,报告了其中82个关于中高危/局部晚期前列腺癌、生化复发和激素治疗副作用问题的共识结果。共识定义为≥75%同意,强共识为≥90%同意;结果反映专家意见,未纳入正式文献回顾和Meta分析。
要点
- 共识定义为≥75%同意,强共识为≥90%同意。
- 投票结果反映国际专家意见,未纳入正式文献回顾和Meta分析。
- APCCC 2022识别出重要未共识领域,值得专门设计试验评估。
核心结论
- 这些国际晚期前列腺癌专家组的投票结果可帮助医生和患者在高级别证据稀少或矛盾的争议领域进行临床管理。
- 诊断和治疗决策应始终根据患者和癌症特征个体化,并纳入当前和新兴临床证据、治疗指南及逻辑和经济因素。
- 始终强烈鼓励参加临床试验。
- APCCC 2022再次识别出重要未共识领域,值得在专门设计的试验中评估。
研究设计与样本
- 2022年晚期前列腺癌共识会议(APCCC 2022)会前由117位国际前列腺癌专家组成的小组使用改良Delphi流程制定198个多选题共识问题。
- 会前通过基于网络的调查对105位直接参与前列腺癌治疗决策的医生小组成员(专家组成员)进行问卷调查。
- 本文报告其中关于主题1-3的82个问题的结果。
主要发现
- 投票结果显示出不同程度的共识。
- 共识定义为≥75%同意,强共识定义为≥90%同意。
关键数值与推荐
- 中高危和局部晚期前列腺癌、局部治疗后生化复发、激素治疗副作用、转移性激素敏感性前列腺癌、非转移性去势抵抗性前列腺癌、转移性去势抵抗性前列腺癌、寡转移和寡进展性前列腺癌共198个多选题。
- 本文报告其中关于主题1-3的82个问题结果。
- 共识定义为≥75%同意,强共识定义为≥90%同意。
临床怎么用
- 投票结果可帮助医生和患者在高级别证据稀少或矛盾的争议领域进行临床管理。
- 诊断和治疗决策应始终根据患者和癌症特征(疾病范围和位置、治疗史、合并症和患者偏好)个体化,并纳入当前和新兴临床证据、治疗指南及逻辑和经济因素。
- 始终强烈鼓励参加临床试验。
局限性
- 结果反映国际专家小组的意见,未纳入正式文献回顾和Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials. PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.
引用
- Gillessen S, Bossi A, Davis ID, et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2022. PMID: 36494221. doi:10.1016/j.eururo.2022.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。